Artificial Intelligence With DEep Learning on COROnary Microvascular Disease
NCT ID: NCT04598997
Last Updated: 2024-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
600 participants
OBSERVATIONAL
2020-10-20
2024-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Automated Echocardiographic Detection of Coronary Artery Disease Using Artificial Intelligence Methods
NCT06314295
Prediction of Coronary Artery Disease Based on Multimodal, Non-contact Information With Artificial Intelligence
NCT06092801
Assessment of Prognosis and Myocardial Reperfusion in Patients with ST-segment-elevation Myocardial Infarction (STEMI) According to Coronary Atherosclerotic Burden.
NCT06876974
Using Retinal Photograph Based AI to Predict Incident Coronary Heart Disease
NCT06695273
Performance Evaluation of Artificial Intelligence Screening Model in Coronary Heart Disease Detection
NCT06658600
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The protocol will be subdivided into 4 steps:
\- Step 1: Patient selection
Data mining to identify and select patients via PMSI data. Patients will be contacted by telephone follow-up to check the participation agreement and collect the primary outcome. Other data from the patient's medical file will be collected through PREDIMED.
\- Step 2: Data annotation
To identify for each patient with successful revascularization according to the usual criteria (TIMI Flow = 3, MBG = 2 or 3 and ST segment resolution \> 70%) whether or not he or she presents, at the time of hospitalization for STEMI, pejorative evolution criteria defined by the occurrence of death or rehospitalization for heart Failure at the time of follow-up . This step requires the expertise of an angioplastician and will result in the generation of a database of 600 cases. To train the algorithm to recognize images in the context of STEMI revascularization, 1000 normal coronary angiographies performed in a stable disease context will also be identified.
\- Step 3: Development of a new method for analyzing coronary angiography images to identify patients with non-optimal revascularization.
Develop using Tensorflow/Keras libraries a supervised Deep Learning AI algorithm trained to identify patients with non-optimal revascularization (patient with poor prognosis). The algorithm will be based on convolutional neural network methodology and the model will be trained using data from the two previous steps. All or part of the sequence of interest will be used at the input of the model which will propose at the output a probability of good or bad prognosis of the patient.The 1000 complementary coronary angiographies will be used to artificially increase the learning base by increasing the number of cases or will be exploited for a transfer learning method.
\- Step 4: Evaluation of the pathophysiological hypothesis.
The main weakness of AI is the "Black Box". That is, the algorithm can predict correctly without knowing how. It is then difficult to link the result to a physiopathological phenomenon and to develop therapeutics. Here we will evaluate the correlation of the algorithm's result with the reference method for measuring CD used in the patients of the Guardiancory study (NCT03087175).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
600 patients involved in the prospective study
These patients will be contacted by telephone follow-up, offered participation in the study and sent the information and non-opposition letter. In case of refusal, data will not be used.
No interventions assigned to this group
1000 patients involved in a non-human study
To train the algorithm to recognize images in the context of STEMI revascularization, 1000 normal coronary angiograms performed in a stable disease context will also be identified.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who have undergone coronary angioplasty revascularization at CHUGA for STEMI from 2015 to 2018 for which images are usable.
* Patient affiliated with social security
* Non-opposition to participation
Exclusion Criteria
* Patient under guardianship or deprived of liberty
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Grenoble
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gilles Barone-Rochette
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Grenoble
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Grenoble Alpes
Grenoble, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-A02379-30
Identifier Type: OTHER
Identifier Source: secondary_id
38RC20.307
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.